ArticleThe American journal of tropical medicine and hygiene2025
Seroprevalence and Factors Associated with Infection with Toxoplasma gondii in Iquitos and Lima, Peru.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative diagnostic performance of metagenomic next-generation sequencing and conventional microbial culture in spinal infections: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Seroprevalence of IgG Antibodies AgainstPathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Toxoplasma gondii infection can pose a significant health risk, particularly among immunocompromised individuals, such as people living with HIV (PLHIV). This study aimed to evaluate the seroprevalence of T. gondii and associated factors among PLHIV and individuals who are HIV negative in two distinct regions of Peru: Iquitos and Lima. We conducted a cross-sectional study, enrolling 281 participants (100 PLHIV and 181 HIV-negative participants). An in-house ELISA was used to detect IgG antibodies against T. gondii after ensuring that its performance was comparable with the commercially available Vircell ELISA kit. Our in-house ELISA demonstrated high reliability, with a positive agreement of 98.3% and a negative agreement of 100% with the Vircell ELISA kit. The overall seroprevalence of T. gondii was 62.3%, with significantly higher rates observed in Iquitos (88.0%) than in Lima (29.3%). People living with HIV showed a notably higher prevalence ratio (PR) for T. gondii seropositivity in both cities, with PRs of 1.18 (95% CI, 1.07-1.29) in Iquitos and 2.29 (95% CI, 1.30-4.05) in Lima. This study highlights the significant regional disparities in T. gondii seroprevalence between Iquitos and Lima, which may be driven by environmental and socioeconomic factors. Our findings underscore the need for region-specific public health interventions to mitigate the impact of T. gondii infections in PLHIV in Peru. Enhanced public health strategies, including improved access to clean water and sanitation in high-risk areas like Iquitos, may be important to reduce the burden of T. gondii and prevent severe complications in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.